AbbVie Inc. (NYSE:ABBV) Shares Sold by B.O.S.S. Retirement Advisors LLC

B.O.S.S. Retirement Advisors LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 90.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,367 shares of the company’s stock after selling 21,638 shares during the period. B.O.S.S. Retirement Advisors LLC’s holdings in AbbVie were worth $421,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Alethea Capital Management LLC purchased a new position in shares of AbbVie during the 2nd quarter worth $488,000. Goodman Advisory Group LLC raised its stake in shares of AbbVie by 3,909.8% in the 2nd quarter. Goodman Advisory Group LLC now owns 13,914 shares of the company’s stock valued at $2,387,000 after acquiring an additional 13,567 shares during the period. Ascent Group LLC lifted its holdings in shares of AbbVie by 4.5% in the 2nd quarter. Ascent Group LLC now owns 25,778 shares of the company’s stock worth $4,421,000 after acquiring an additional 1,102 shares during the last quarter. Annandale Capital LLC boosted its position in shares of AbbVie by 686.6% during the 2nd quarter. Annandale Capital LLC now owns 29,106 shares of the company’s stock worth $4,992,000 after purchasing an additional 25,406 shares during the period. Finally, Copperwynd Financial LLC raised its position in AbbVie by 29.5% in the second quarter. Copperwynd Financial LLC now owns 1,562 shares of the company’s stock valued at $289,000 after purchasing an additional 356 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the sale, the senior vice president now owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.25% of the company’s stock.

AbbVie Stock Down 0.4 %

AbbVie stock opened at $170.05 on Friday. The stock has a market capitalization of $300.51 billion, a price-to-earnings ratio of 59.05, a PEG ratio of 1.68 and a beta of 0.58. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The stock has a 50 day moving average of $175.84 and a two-hundred day moving average of $184.66. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.92 by $0.08. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The company had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.28 billion. During the same quarter last year, the business earned $2.95 EPS. The business’s revenue was up 3.8% on a year-over-year basis. As a group, research analysts expect that AbbVie Inc. will post 10.06 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.86%. This is an increase from AbbVie’s previous quarterly dividend of $1.55. The ex-dividend date is Wednesday, January 15th. AbbVie’s dividend payout ratio is 227.78%.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Argus upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. Sanford C. Bernstein began coverage on AbbVie in a research report on Thursday, October 17th. They issued a “market perform” rating and a $203.00 target price for the company. Daiwa America cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 5th. Truist Financial dropped their price objective on shares of AbbVie from $215.00 to $211.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, JPMorgan Chase & Co. dropped their price target on shares of AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $205.50.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.